Search clinical trials for: GCC-4401C

Total 1605 results

Genentech, Inc.

Completed

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer
M.D. Anderson Cancer Center
Loxo Oncology, Inc.; The Leukemia and Lymphoma Society

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Leukemia

United States
AbbVie

Recruiting

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Hematologic Malignancies

United States, Australia
Otto Metzger, MD
Genentech, Inc.

Active, not recruiting

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Victor Tapson, MD
Bristol-Myers Squibb

Terminated

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism (SAFE-LYSE)

Pulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute Massive

United States
Genentech, Inc.

Completed

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects (QCL117578)

Healthy Volunteer

United Kingdom
GlaxoSmithKline

Completed

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

Carcinoma, Renal Cell
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Graft-versus-Host Disease

United States
Celgene

Active, not recruiting

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Lymphoma, Non-Hodgkin

United States, Germany, Puerto Rico
National Cancer Institute (NCI)

Completed

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
Amgen

Completed

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. (UNVEIL)

Parapsoriasis

United States
Ramathibodi Hospital
Khon Kaen University

Completed

Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome

Impingement Shoulder
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Uma Borate

Recruiting

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Neutrophilic Leukemia | Myeloid Neoplasm | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
AbbVie
Genentech, Inc.

Completed

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Non-Hodgkin's Lymphoma

United States
AstraZeneca
QuintilesIMS, Inc.

Withdrawn

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease (ASTUTE)

Chronic Obstructive Pulmonary Disease
Celgene

Completed

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

Lymphoma, Non-Hodgkin

United States, Spain, China, Belgium, France, United Kingdom, Israel, Turkey, Russian Federation, Italy, Brazil, Czechia, Portugal, Germany, Japan, Poland, Puerto Rico
M.D. Anderson Cancer Center
Celgene; Onyx Therapeutics, Inc.

Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Cairo University

Unknown

Reminerlization Potential of Innovative Biomimetic Material in Caries White Spot Lesions

White Spot Lesion of Tooth

Egypt
University of Sao Paulo

Completed

Primary Molars Restorations With Encapsulated or Hand-Mixed Glass Ionomer: Clinical Trial

Dental Caries

Brazil
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
AbbVie
Roche-Genentech

Active, not recruiting

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Multiple Myeloma

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, Turkey, Ukraine, United Kingdom
Medical College of Wisconsin

Completed

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE)

Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
AbbVie
Celgene

Terminated

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, United Kingdom
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

HIV Infection

United States
Novartis Pharmaceuticals

Completed

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Parkinson's Disease With End of Dose Wearing Off

United States, Puerto Rico
Alcon Research

Terminated

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
KAZM Pharmaceuticals Inc.
McMaster University

Not yet recruiting

Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty

Postsurgical Pain

Canada
M.D. Anderson Cancer Center
Celgene Corporation

Active, not recruiting

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

Lymphoma

United States
National Human Genome Research Institute (NHGRI)

Completed

Treatment Strategies for Children With Smith-Magenis Syndrome

Mental Retardation | Sleep Disorders, Circadian Rhythm | Developmental Delay Disorders | Chromosome Deletion | Self Injurious Behavior

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Seagen Inc.

Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Metastatic Solid Tumor | Brain Metastases

United States
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Mifepristone Treatment of Alcohol Use Disorder

Alcohol Dependence | Alcoholism | Alcohol Use Disorders | Alcohol Abuse

United States
Genentech, Inc.

Completed

Study of Cobimetinib in Participants With Solid Tumors

Solid Tumor

United States
University of Roma La Sapienza

Unknown

Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure

Heart Failure | Renal Insufficiency

Italy
M.D. Anderson Cancer Center
Daiichi Sankyo

Recruiting

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Lymphoma

United States
University of Florida
U.S. Army Medical Research and Development Command

Recruiting

Twice Weekly Steroids and Exercise as Therapy for DMD

Duchenne Muscular Dystrophy (DMD)

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Terminated

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Amgen

Completed

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST)

Arthritis, Psoriatic

United States, Spain, Netherlands, Canada, France, Russian Federation, Belgium, Austria, Germany, Italy, United Kingdom
University of Arkansas

Completed

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Multiple Myeloma

United States
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom

Search clinical trials for: GCC-4401C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations